142 related articles for article (PubMed ID: 38246144)
1. Facilitated Subcutaneous Immunoglobulin Treatment Increases the Quality of Life and Decreases the Number of Infections and Hospitalizations in Children with Primary Immunodeficiencies.
Erbaş Açıcı N; Topyildiz E; Aygün A; Geyik M; Edeer Karaca N; Aksu G; Kutukculer N
Int Arch Allergy Immunol; 2024; 185(4):382-391. PubMed ID: 38246144
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder.
Sarı G; Güven Bilgin B; Yılmaz E; Aytac G; Edeer Karaca N; Aksu G; Kutukculer N
Eur Ann Allergy Clin Immunol; 2021 Jul; 53(4):177-184. PubMed ID: 33191716
[No Abstract] [Full Text] [Related]
3. Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies.
Wiesik-Szewczyk E; Sołdacki D; Paczek L; Jahnz-Różyk K
Front Immunol; 2020; 11():981. PubMed ID: 32670265
[TBL] [Abstract][Full Text] [Related]
4. Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.
Li Z; Follman K; Freshwater E; Engler F; Yel L
J Clin Immunol; 2023 Nov; 43(8):2127-2135. PubMed ID: 37773562
[TBL] [Abstract][Full Text] [Related]
5. Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule.
Hustad NB; Degerud HM; Hjelmerud I; Fraz MSA; Nordøy I; Trøseid M; Fevang B; Aukrust P; Jørgensen SF
Front Immunol; 2021; 12():670547. PubMed ID: 34012453
[TBL] [Abstract][Full Text] [Related]
6. Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.
Ponsford M; Carne E; Kingdon C; Joyce C; Price C; Williams C; El-Shanawany T; Williams P; Jolles S
Clin Exp Immunol; 2015 Dec; 182(3):302-13. PubMed ID: 26288095
[TBL] [Abstract][Full Text] [Related]
7. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
[TBL] [Abstract][Full Text] [Related]
8. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.
Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I
Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
Stein MR; Koterba A; Rodden L; Berger M
Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
[TBL] [Abstract][Full Text] [Related]
10. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases.
Baumann U; Fasshauer M; Pausch C; Wittkowski H; Hermann C; Pittrow D; Borte M
Immunotherapy; 2022 Feb; 14(2):135-143. PubMed ID: 34743590
[No Abstract] [Full Text] [Related]
11. Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases.
Speth F; Haas JP; Hinze CH
Pediatr Rheumatol Online J; 2016 Sep; 14(1):52. PubMed ID: 27623619
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Experience of Subcutaneous Immunoglobulin Therapy in Pediatric Primary Immunodeficient Patients with Low and Normal Body Weight.
Gul Y; Kapakli H; Guner SN; Alan HB; Hazar E; Keles S; Reisli I
J Clin Immunol; 2022 Jan; 42(1):64-71. PubMed ID: 34617265
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.
Li Z; Follman K; Freshwater E; Engler F; Yel L
Int Immunopharmacol; 2024 Feb; 128():111447. PubMed ID: 38185032
[TBL] [Abstract][Full Text] [Related]
14. Quality of Life Evaluation in Saudi Arabian Pediatric Patients with Primary Immunodeficiency Diseases Receiving 20% Subcutaneous IgG Infusions at Home.
Al-Saud B; AlRumayyan N; Alfattani A; Awwad SA; Al Saud D; Mohammed R; Albuhairi S; Elshorbagi S; Balhareth SS; Al-Dhekri H; Arnaout R; De Vol EB; Al-Mousa H
J Clin Immunol; 2023 Aug; 43(6):1360-1366. PubMed ID: 37145392
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency.
Gupta S; Kobayashi RH; Litzman J; Cherwin L; Hoeller S; Kreuwel H
Expert Rev Clin Immunol; 2023 Jan; 19(1):7-17. PubMed ID: 36346032
[TBL] [Abstract][Full Text] [Related]
16. Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG.
Anterasian C; Duong R; Gruenemeier P; Ernst C; Kitsen J; Geng B
J Clin Immunol; 2019 Nov; 39(8):814-822. PubMed ID: 31673923
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina.
Bezrodnik L; Gómez Raccio A; Belardinelli G; Regairaz L; Díaz Ballve D; Seminario G; Moreira I; Riganti C; Cantisano C; Díaz H; Di Giovanni D
J Clin Immunol; 2013 Oct; 33(7):1216-22. PubMed ID: 23846854
[TBL] [Abstract][Full Text] [Related]
18. [Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain].
Maroto Hernando M; Soler Palacín P; Martin Nalda N; Oliveras Arenas M; Español Boren T; Figueras Nadal C
An Pediatr (Barc); 2009 Feb; 70(2):111-9. PubMed ID: 19217565
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
Jolles S; Rojavin MA; Lawo JP; Nelson R; Wasserman RL; Borte M; Tortorici MA; Imai K; Kanegane H
J Clin Immunol; 2018 Nov; 38(8):864-875. PubMed ID: 30415311
[TBL] [Abstract][Full Text] [Related]
20. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.
Abolhassani H; Sadaghiani MS; Aghamohammadi A; Ochs HD; Rezaei N
J Clin Immunol; 2012 Dec; 32(6):1180-92. PubMed ID: 22730009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]